Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)

Go back to Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)
AmerElite Solutions, Inc. New (NASDAQ: AMRX) Delayed: 19.18 -0.07 (0.36%)
Previous Close $19.25    52 Week High $0.19 
Open $19.28    52 Week Low $0.07 
Day High $19.39    P/E N/A 
Day Low $18.94    EPS $-0.01 
Volume 2,429,166